Office Evaluation of Male Sexual Dysfunction

Urologic Clinics of North America

Volumn 34, Issue 4, 2007, Pages 463-482

  Seftel, Allen D ^a   Miner, Martin M ^b   Kloner, Robert A ^c   Althof, Stanley E ^a,d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b BROWN UNIVERSITY   (United States)

^c GOOD SAMARITAN HOSPITAL   (United States)

^d Center for Marital and Sexual Health of South Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CARDIOVASCULAR AGENT; DAPOXETINE; FLUVOXAMINE; LIDOCAINE; LUTEINIZING HORMONE; PHOSPHODIESTERASE V INHIBITOR; PROLACTIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE BINDING GLOBULIN; SILDENAFIL; TADALAFIL; TESTOSTERONE; TESTOSTERONE ENANTATE; VARDENAFIL; VASODILATOR AGENT;

AGE DISTRIBUTION; AZOOSPERMIA; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR DISEASE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EPIDEMIOLOGICAL DATA; ERECTILE DYSFUNCTION; HEART AUSCULTATION; HIGH RISK PATIENT; HISTORY OF MEDICINE; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOGONADISM; IMPAIRED GLUCOSE TOLERANCE; IMPOTENCE; ISCHEMIC HEART DISEASE; LOW CALORY DIET; LUNG AUSCULTATION; MAJOR DEPRESSION; MALE SEXUAL DYSFUNCTION; MEDICAL EXAMINATION; METABOLIC SYNDROME X; MONOTHERAPY; NEUROLOGIC EXAMINATION; NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY; OBSESSIVE COMPULSIVE DISORDER; OPTIC NERVE DISEASE; PATIENT COUNSELING; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PREMATURE EJACULATION; PRIORITY JOURNAL; PSYCHOSEXUAL DISORDER; PSYCHOTHERAPY; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALIVA LEVEL; SCORING SYSTEM; STRUCTURED INTERVIEW; TESTOSTERONE BLOOD LEVEL; WAIST CIRCUMFERENCE; WORLD HEALTH ORGANIZATION;

ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; MALE; OFFICE VISITS; PHYSICAL EXAMINATION; QUESTIONNAIRES;

EID: 35848938967     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.08.004     Document Type: Review

References (114)

1. Krane R.J., and Goldstein I. Saenz de Tejada I. Impotence. N Engl J Med 321 (1989) 1648-59
2. Rosen R.C., and Leiblum S.R. Erectile disorders: an overview of historical trends and clinical perspectives. In: Rosen R.C., and Leiblum S.R. (Eds). Erectile disorders: assessment and treatment (1992), Guilford, New York 3-26
3. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 270 1 (1993) 83-90
4. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151 1 (1994) 54-61
5. Laumann E., Paik A., and Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281 6 (1999) 537-544
6. Masumori N., Tsukamoto T., Kumamoto Y., et al. Decline of sexual function with age in Japanese men compared with American men-results of two community-based studies. Urology 54 (1999) 335-344
7. Marumo K., Nakashima J., and Murai M. Age-related prevalence of erectile dysfunction in Japan: assessment by the International Index of Erectile Function. Int J Urol 8 2 (2001) 53-59
8. Saigal C.S., Wessels H., Pace J., et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 166 (2006) 207-212
9. Seftel A.D., and Sun P. Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 171 6 Pt 1 (2004) 2341-2345
10. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291 24 (2004) 2978-2984
11. Eaton C.B., Liu Y.L., Mittleman M.A., et al. A retrospective study of the relationship between biomarkers of atherosclerosis and erectile dysfunction in 988 men. Int J Impot Res 19 2 (2007) 218-225
12. Min J.K., Williams K.A., Okwuosa T.M., et al. Prediction of coronary heart disease by erectile dysfunction in men referred for nuclear stress testing. Arch Intern Med 166 (2006) 201-206
13. Grover S.A., Lowensteyn I., Kaouache M., et al. The prevalence of erectile dysfunction in the primary care setting. Arch Intern Med 166 (2006) 213-219
14. Thompson I.M., Tangen C.M., Goodman P.J., et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 294 23 (2005) 2996-3002
15. Montorsi P., Ravagnani P.M., Galli S., et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 27 22 (2006) 2632-2639
16. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 96 2 (2005) 313-321
17. Laumann E.O., Nicolosi A., Glasser D.B., et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the global study of sexual attitudes and behaviors. Int J Impot Res 17 (2005) 39-57
18. de Boer B.J., Bots M.L., Lycklama a Nijeholt A.A., et al. The prevalence of bother, acceptance, and need for help in men with erectile dysfunction. J Sex Med 2 (2005) 445-450
19. Korenman S.G. New insights into erectile dysfunction: a practical approach. Am J Med 105 (1998) 135-144
20. Fugl-Meyer A.R., Lodnert G., Branholm I.B., et al. On life satisfaction in male erectile dysfunction. Int J Impot Res 9 (1997) 141-148
21. Rosen R.C. Quality of life assessment in sexual dysfunction trials. Int J Impot Res 10 (1998) S21-S23
22. Gades N.M., Nehra A., Jacobson D.J., et al. Association between smoking and erectile dysfunction: a population-based study. Am J Epidemiol 161 4 (2005) 346-351
23. Bacon C.G., Mittleman M.A., Kawachi I., et al. A prospective study of risk factors for erectile dysfunction. J Urol 176 1 (2006) 217-221
24. Hatzichristou D., Rosen R.C., Broderick G., et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 1 1 (2004) 49-57
25. Mulligan T., Frick M.F., Zuraw Q.C., et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60 7 (2006) 762-769
26. Seftel A.D. Male hypogonadism. Part I: epidemiology of hypogonadism. Int J Impot Res 18 2 (2006) 115-120
27. Rhoden E.L., and Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350 (2004) 482-492
28. Harman S.M., Metter E.J., Tobin J.D., et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86 (2001) 724-731
29. Morley J.E., Kaiser F.E., Perry III H.M., et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46 (1997) 410-413
30. Snyder P.J. Effects of age on testicular function and consequences of testosterone treatment. J Clin Endocrinol Metab 86 (2001) 2369-2372
31. Vermeulen A. Androgen replacement therapy in the aging male: a critical evaluation. J Clin Endocrinol Metab 86 (2001) 2380-2390
32. Bremner W.J., Vitiello M.V., and Prinz P.N. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 56 (1983) 1278-1281
33. Bhasin S., Cunningham G.R., Hayes F., et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91 (2006) 1995-2010
34. Shames D., Gassman A., and Handelsman H. Commentary: guideline for male testosterone therapy: a regulatory perspective. J Clin Endocrinol Metab 92 2 (2007) 414-415
35. Svartberg J. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res 19 2 (2007) 124-128
36. Carson C., and Gunn K. Premature ejaculation: definition and prevalence. Int J Impot Res 18 Suppl 1 (2006) S5-S13
37. Segraves R.T. Rapid ejaculation: a review of nosology, prevalence and treatment. Int J Impot Res 18 Suppl 1 (2006) S24-S32
38. Fugl-Meyer A.R., Sjogren K., and Fugl-Meyer K.S. Sexual disabilities, problems, and satisfaction in 18-74 year old Swedes. Scand J Sexol 3 (1999) 79-105
39. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text revision (DSM-IV-TR) (2000), American Psychiatric Association, Washington, DC
40. Patrick D.L., Althof S.E., Pryor J.L., et al. Premature ejaculation: an observational study of men and their partners. J Sex Med 2 3 (2005) 358-367
41. Waldinger M.D., and Schweitzer D.H. Changing paradigms from an historical DSM-III and DSM-IV view towards an evidence based definition of premature ejaculation. Part II: proposals for DSM-V and ICD-11. J Sex Med 3 (2006) 693-705
42. Waldinger M.D. Emerging drugs for premature ejaculation. Expert Opin Emerg Drugs 11 1 (2006) 99-109
43. Rosen R.C., Cappelleri J.C., Smith M.D., et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11 6 (1999) 319-326
44. Morley J.E., Charlton E., Patrick P., et al. Androgen deficiency in aging males (ADAM): validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49 9 (2000) 1239-1242
45. Weissman M.M., Sholomskas D., Pottenger M., et al. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 106 3 (1977) 203-214
46. Nitti V.W., Kim Y., and Combs A.J. Correlation of the AUA symptom index with urodynamics in patients with suspected benign prostatic hyperplasia. Neurourol Urodyn 13 5 (1994) 521-527 [discussion 527-9]
47. Corona G., Mannucci E., Petrone L., et al. Psycho-biological correlates of free-floating anxiety symptoms in male patients with sexual dysfunctions. J Androl 27 1 (2006) 86-93
48. Braun M., Wassmer G., Klotz T., et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 12 (2000) 305
49. van Moorselaar R.J., Hartung R., Emberton M., et al., ALF-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 95 4 (2005) 603-608
50. Rees R.W., Foxwell N.A., Ralph D.J., et al. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 170 6 Pt 1 (2003) 2517-2522
51. Cappelleri J.C., and Rosen R.C. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 17 4 (2005) 307-319
52. Morley J.E., Charlton E., Patrick P., et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metab Clin Exp 49 9 (2000) 1239-1242
53. Martin-Morales A., Haro J.M., Beardsworth A., et al., EDOS Group. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the Erectile Dysfunction Observational Study (EDOS). Eur Urol 51 2 (2007) 541-550
54. Lowy M., Collins S., Bloch M., et al. Quality of erection questionnaire correlates: change in erection quality with erectile function, hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction. J Sex Med 4 1 (2007) 83-92
55. Padma-Nathan H. Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness. Int J Impot Res 18 5 (2006) 423-431
56. Eardley I., Montorsi F., Jackson G., et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int 100 1 (2007) 122-129
57. Seftel A.D. Challenges in oral therapy for erectile dysfunction. J Androl 23 6 (2002) 729-736
58. Levine S.B., Althof S.E., Turner L.A., et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 141 1 (1989) 54-57
59. Turner L.A., Althof S.E., Levine S.B., et al. External vacuum devices in the treatment of erectile dysfunction: a one-year study of sexual and psychosocial impact. J Sex Marital Ther 17 2 (1991) 81-93
60. Padma-Nathan H., Hellstrom W.J., Kaiser F.E., et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 336 1 (1997) 1-7
61. Sadeghi-Nejad H. Penile prosthesis surgery: a review of prosthetic devices and associated complications. J Sex Med 4 2 (2007) 296-309
62. Jackson G., Montorsi P., and Cheitlin M.D. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. Urology 68 Suppl 3 (2006) 47-60
63. Kloner R.A., Jackson G., Hutter A.M., et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 97 12 (2006) 1778-1784
64. Hayreh S.S. Anterior ischemic optic neuropathy (1975), Springer Verlag, New York
65. Hayreh S.S. Anterior ischemic optic neuropathy. Arch Neurol 38 (1981) 675-678
66. Hayreh S.S. Anterior ischemic optic neuropathy: differentiation of arteritic from non-arteritic type and its management. Eye 4 (1990) 25-41
67. Johnson L.N., and Arnold A.C. Incidence of non-arteritic anterior ischemic optic neuropathy: population based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 14 (1994) 38-44
68. Ischemic Optic Neuropathy Decompression Trial (IONDT) Research Group. Manual of operations. Baltimore: University of Maryland at Baltimore, 1992;1:1-2.
69. Hattenhauser M.G., Leavitt J.A., Hodge D.O., et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 123 (1997) 103-107
70. Buono L.M., Foroozan R., Sergott R.C., et al. Nonarteritic anterior ischemic optic neuropathy. Curr Opin Ophthalmol 13 (2002) 357-361
71. Rucker J.C., Biousse V., and Newman N.J. Ischemic optic neuropathies. Curr Opin Neurol 17 (2004) 27-35
72. Cunningham A.V., and Smith K.H. Anterior ischemic optic neuropathy associated with Viagra. J Neuroophthalmol 21 (2001) 22-25
73. Egan R.A., and Pomeranz H.D. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Ophthalmol 118 (2000) 291-292
74. Pomeranz H.D., Smith K.H., Hart W.M., et al. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 109 (2002) 584-587
75. Pomeranz H.D., and Bhavsar A.R. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol 25 (2005) 9-13
76. Escaravage G.K., Wright J.D., and Givre S.J. Tadalafil associated with anterior ischemic optic neuropathy. Arch Ophthalmol 123 (2005) 399-400
77. Laties A.M., and Zrenner E. Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 21 (2002) 485-506
78. Marmor M.F., and Kessler R. Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol 44 (1999) 153-162
79. McGwin G., Vaphiades M.S., Hall T.A., et al. Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol 90 2 (2006) 154-157
80. Gorkin L., Hvidsten K., Sobel R.E., et al. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 60 4 (2006) 500-503
81. Miner M.M., and Sadovsky R. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. Cleve Clin J Med 74 Suppl 3 (2007) S38-S46
82. Miner M.M., and Seftel A.D. Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?. Int J Clin Pract 61 4 (2007) 622-632
83. Morgentaler A., and Rhoden E.L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 68 6 (2006) 1263-1267
84. Morales A. Monitoring androgen replacement therapy: testosterone and prostate safety. J Endocrinol Invest 28 Suppl 3 (2005) 122-127
85. Wiren S., Stocks T., Rinaldi S., et al. Androgens and prostate cancer risk: a prospective study. Prostate 67 11 (2007) 1230-1237
86. Travis R.C., Key T.J., Allen N.E., et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121 6 (2007) 1331-1338
87. Gann P.H., Hennekens C.H., Ma J., et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 16 (1996) 1118-1126
88. Seftel A.D., Mack R.J., Secrest A.R., et al. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl 25 (2004) 963-972
89. Barqawi A., O'Donnell C., Kumar R., et al. Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse population: data from the Prostate Cancer Awareness Week (PCAW). Int J Impot Res 17 (2005) 370-374
90. Gray P.B., Singh A.B., Woodhouse L.J., et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 90 (2005) 3838-3846
91. Wang C., Cunningham G., Dobs A., et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89 (2004) 2085-2098
92. Rosenthal B.D., May N.R., Metro M.J., et al. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 67 (2006) 571-574
93. Shabsigh R., Kaufman J.M., Steidle C., et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172 (2004) 658-663
94. Bocchio M., Desideri G., Scarpelli P., et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 171 (2004) 1601-1604
95. Aversa A., Isodori A.M., Spera G., et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58 (2003) 632-638
96. Aversa A., Isidori A.M., Greco E.A., et al. Hormonal supplementation and erectile dysfunction. Eur Urol 45 (2004) 535-538
97. Nieschlag E., Swerdloff R., Behre H.M., et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 27 2 (2006) 135-137
98. Marks L.S., Mazer N.A., Mostaghel E., et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296 19 (2006) 2351-2361
99. Seftel A. Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. Int J Impot Res 18 3 (2006) 223-228
100. Seftel A. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 19 1 (2007) 2-24
101. Waldinger M.D., Zwinderman A.H., Olivier B., et al. The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med 4 4i (2007) 1028-1037
102. Pryor J.L., Althof S.E., Steidle C., et al., Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 368 9539 (2006) 929-937
103. Arafa M., and Shamloul R. Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire. Int J Impot Res 18 6 (2006) 534-538
104. Available at: http://www.fda.gov/cder/drug/antidepressants/ antidepressants_label_chang e_2007.pdf. Accessed October 18, 2007.
105. Dinsmore W.W., Hackett G., Goldmeier D., et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 99 2 (2007) 369-375
106. Morales A., Barada J., and Wyllie M.G. A review of the current status of topical treatments for premature ejaculation. BJU Int 100 3 (2007) 493-501
107. Banner L.L., and Anderson R.U. Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. J Sex Med 4 4 Pt 2 (2007) 1117-1125
108. Althof S.E. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res 14 Suppl 1 (2002) S99-S104
109. Althof S., Rosen R., Symonds T., et al. Development and validation of a new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation. J Sex Med 3 3 (2006) 465-475
110. Symonds T., Perelman M., Althof S., et al. Further evidence of the reliability and validity of the premature ejaculation diagnostic tool. Int J Impot Res 19 5 (2007) 521-525
111. Rosen R.C., Catania J.A., Althof S.E., et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology 69 5 (2007) 805-809
112. Ghanem H., Zaazaa A., Kamel I., et al. Short-term use of sildenafil in the treatment of unconsummated marriages. Int J Impot Res 18 1 (2006) 52-54
113. Althof S.E., and Weider M. Psychotherapy for erectile dysfunction: more relevant than ever. Endocrine 23 2-3 (2004) 131-134
114. Sato Y., Tanda H., Kato S., et al. Prevalence of major depressive disorder in self-referred patients in a late onset hypogonadism clinic. Int J Impot Res 19 4 (2007) 407-410